Caricamento...
A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma
Rituximab is widely used for the treatment of non-Hodgkin lymphoma, being a key component in most therapeutic regimens. Administration of the intravenous (IV) formulation is lengthy and places a significant burden on health care resources and patient quality of life. A subcutaneous (sc) formulation...
Salvato in:
| Pubblicato in: | Curr Oncol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Multimed Inc.
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5330627/ https://ncbi.nlm.nih.gov/pubmed/28270723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.24.3470 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|